These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 15743932)

  • 1. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation.
    Kandimalla KK; Curran GL; Holasek SS; Gilles EJ; Wengenack TM; Poduslo JF
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1370-8. PubMed ID: 15743932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
    Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF
    J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease.
    Poduslo JF; Curran GL; Wengenack TM; Malester B; Duff K
    Neurobiol Dis; 2001 Aug; 8(4):555-67. PubMed ID: 11493021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the generation of amyloid beta-protein in endoplasmic reticulum and Golgi.
    Xia W; Zhang J; Ostaszewski BL; Kimberly WT; Seubert P; Koo EH; Shen J; Selkoe DJ
    Biochemistry; 1998 Nov; 37(47):16465-71. PubMed ID: 9843412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
    van Groen T; Kiliaan AJ; Kadish I
    Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiological and biophysical factors that influence Alzheimer's disease amyloid plaque targeting of native and putrescine modified human amyloid beta40.
    Kandimalla KK; Curran GL; Holasek SS; Gilles EJ; Wengenack TM; Ramirez-Alvarado M; Poduslo JF
    J Pharmacol Exp Ther; 2006 Jul; 318(1):17-25. PubMed ID: 16565169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice.
    LaRue B; Hogg E; Sagare A; Jovanovic S; Maness L; Maurer C; Deane R; Zlokovic BV
    J Neurosci Methods; 2004 Sep; 138(1-2):233-42. PubMed ID: 15325132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical.
    Lee HJ; Zhang Y; Zhu C; Duff K; Pardridge WM
    J Cereb Blood Flow Metab; 2002 Feb; 22(2):223-31. PubMed ID: 11823720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropathology of mice carrying mutant APP(swe) and/or PS1(M146L) transgenes: alterations in the p75(NTR) cholinergic basal forebrain septohippocampal pathway.
    Jaffar S; Counts SE; Ma SY; Dadko E; Gordon MN; Morgan D; Mufson EJ
    Exp Neurol; 2001 Aug; 170(2):227-43. PubMed ID: 11476589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease.
    El Tannir El Tayara N; Delatour B; Le Cudennec C; Guégan M; Volk A; Dhenain M
    Neurobiol Dis; 2006 Apr; 22(1):199-208. PubMed ID: 16337798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen treatment improves spatial learning in APP + PS1 mice but does not affect beta amyloid accumulation and plaque formation.
    Heikkinen T; Kalesnykas G; Rissanen A; Tapiola T; Iivonen S; Wang J; Chaudhuri J; Tanila H; Miettinen R; Puoliväli J
    Exp Neurol; 2004 May; 187(1):105-17. PubMed ID: 15081593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurodegenerative changes associated with beta-amyloid deposition in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes.
    Kurt MA; Davies DC; Kidd M; Duff K; Rolph SC; Jennings KH; Howlett DR
    Exp Neurol; 2001 Sep; 171(1):59-71. PubMed ID: 11520121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased Abeta secretion by cells expressing familial Alzheimer's disease-linked mutant presenilin 1.
    Shimojo M; Sahara N; Murayama M; Ichinose H; Takashima A
    Neurosci Res; 2007 Mar; 57(3):446-53. PubMed ID: 17210196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered levels and distribution of IGF-II/M6P receptor and lysosomal enzymes in mutant APP and APP + PS1 transgenic mouse brains.
    Amritraj A; Hawkes C; Phinney AL; Mount HT; Scott CD; Westaway D; Kar S
    Neurobiol Aging; 2009 Jan; 30(1):54-70. PubMed ID: 17561313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prion protein (PrPc) promotes beta-amyloid plaque formation.
    Schwarze-Eicker K; Keyvani K; Görtz N; Westaway D; Sachser N; Paulus W
    Neurobiol Aging; 2005; 26(8):1177-82. PubMed ID: 15917101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease.
    Lafay-Chebassier C; Paccalin M; Page G; Barc-Pain S; Perault-Pochat MC; Gil R; Pradier L; Hugon J
    J Neurochem; 2005 Jul; 94(1):215-25. PubMed ID: 15953364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
    Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
    J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
    Güntert A; Döbeli H; Bohrmann B
    Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of in vivo MRI detectable thalamic amyloid plaques from APP/PS1 mice.
    Dhenain M; El Tannir El Tayara N; Wu TD; Guégan M; Volk A; Quintana C; Delatour B
    Neurobiol Aging; 2009 Jan; 30(1):41-53. PubMed ID: 17588710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer's disease.
    Wirths O; Weis J; Szczygielski J; Multhaup G; Bayer TA
    Acta Neuropathol; 2006 Apr; 111(4):312-9. PubMed ID: 16520967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.